Prediction Case File
YouTubeTracking Live

3 SMALL CAPS Under $10 with Big Potential

3 extracted signals · 0 resolved · 3 still active

MarketBeat profile imageMarketBeat18 Jul 2026, 15:00 UTC
Video preview for 3 SMALL CAPS Under $10 with Big Potential
Signals
3
Eligible signals in this source
Open
3
Still being tracked
Resolved
0
Evaluable outcomes
Successful
0
Canonical correct result
Failed
0
Canonical failed result
Resolved success
Not enough data
Open and excluded signals omitted
Source overview

AI-generated source summary

The analysis focuses on three small-cap stocks under $10, each identified with strong fundamentals and growth potential. The first stock, AVAN Health (AVAH), is a home healthcare provider with significant revenue from Medicare and Medicaid. It demonstrated 16% revenue growth last year and has increased its 2026 revenue guidance twice, indicating strong performance above management expectations. Its current price is $9.70, with a target price of $10.56 and a fail bound at $8.00, suggesting a bullish outlook. The second stock, GNW (Genworth Financial), is an insurance company with a $7 billion annual revenue and a P/E ratio of 17, below the S&P 500 average. Despite a complex history and a past decline due to long-term care policies, recent performance shows a clear upward trend over the last five years. It is considered profitable with 55% net profit margins in its PMI business. Its current price is $9.20, with a target of $15.25 and a fail bound at $7.00. The third stock, EGAN (eGain), is a micro-cap company with a $175 million market cap, founded in 1997. It is characterized as a resilient 'cockroach' company. The analysis suggests a potential for significant price movement, setting a target of $15.00 and a fail bound at $4.00, with a current price of $6.57. The company's customer relationship management software handling emails and databases is highlighted as an area where AI could improve efficiency. All three stocks are presented with a bullish outlook.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    3 eligible signals linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Live evaluation in progress

    3 signals remain active.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

MarketBeat

Tracked signals
988
Historical success
42.8%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.